The strong Q2 beat and reaffirmed upper-end guidance confirm commercial momentum. The Regeneron partnership and convertible bond refinancing strengthen the balance sheet and pipeline optionality. Key catalysts to watch: Pixclara PDUFA date September 11, 2026, and Zircaix BLA resubmission timing.
Drugs in focus
TLX drug pipeline →TLX591-Tx
● Neutral Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Next catalyst
- None dated
What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review Named in filing
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2)) Named in filing
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete Named in filing
- ◆ ITM-11 4/10 Phase 3 (completed)
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+60- T+0 · Jul 21 $10.92entry
- T+1 · 4mo ago −5.49%α −5.38% · $10.32
- T+5 · 4mo ago −8.61%α −7.38% · $9.98
- T+20 · 3mo ago +8.79%α +6.23% · $11.88
- T+60 · 5w ago 0.00%α −3.97% · $10.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY). FY2026 revenue guidance is tracking at the upper end of US$950M-$970M, with total 2026 revenue and other income expected to exceed US$1B including a US$40M non-refundable payment from Regeneron. The company also announced a strategic collaboration with Regeneron, a US$600M convertible bond refinancing extending maturities, and FDA alignment to advance the ProstACT Phase 3 trial of TLX591-Tx.
Key Facts
- Q2 2026 group revenue of US$247M, up 21% YoY and 7% QoQ
- Precision Medicine revenue of US$202M, up 30% YoY
- FY2026 revenue guidance tracking at upper end of US$950M-$970M, plus US$40M Regeneron payment
- R&D expenditure guidance updated to US$230M-$270M
- Entered strategic collaboration with Regeneron to develop next-gen radiopharmaceutical therapies
- Completed US$600M convertible bond refinancing, extending maturities to 2031
- FDA alignment on ProstACT Global Phase 3 trial of TLX591-Tx to advance to Part 2 in the US
- BiPASS Phase 3 study of Illuccix and Gozellix enrolled 338 patients
Financial Impact
Revenue growth of 21% YoY to US$247M in Q2, with FY2026 guidance implying >US$1B total revenue and other income
Risk Factors
- R&D expenditure guidance increased to US$230M-$270M, potentially pressuring near-term profitability
- Pipeline execution risk for late-stage trials (TLX591-Tx, TLX101-Tx, TLX250-Tx)
- Regulatory risk for Pixclara and Zircaix approvals
- Convertible bond issuance adds debt, though extends maturities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-048922 |
| Document: telix-6kforq22026tradingup.htm | 0001628280-26-048922 |
| Document: 0001628280-26-048922-index-headers.html | 0001628280-26-048922 |
| Document: 0001628280-26-048922-index.html | 0001628280-26-048922 |
| Document: 0001628280-26-048922.txt | 0001628280-26-048922 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers